drugset / Trial / NCT06259526

A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression

NCT06259526

Phase 2 Completed 267 enrolled Tasly Pharmaceutical Group Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression

Timeline

Start
2023-12-26
Primary completion
2024-10-23
Completion
2024-10-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule
Subject JS1-1-01 Unknown 25 mg
Subject JS1-1-01 Unknown 50 mg
Subject JS1-1-01 Unknown 75 mg

Indications